FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
The U.S. FDA approved Sanofi’s BTK inhibitor Wayrilz (rilzabrutinib) to treat adult persistent or chronic immune thrombocytopenia (ITP) who failed prior therapies—a milestone from Sanofi’s $3.7B Principia acquisition.
Sanofi plans U.S. availability in September 2025, setting a list price of $17,500 per month (actual patient cost will vary by insurance). Analysts forecast $2–5B peak sales as Sanofi broadens its rare disease & immunology portfolio beyond Dupixent. Wayrilz targets BTK to dampen overactive immune signaling, helping raise dangerously low platelet counts in ITP.
You May Interested In
High Quality β-Nicotinamide adenine dinucleotide CAS 53-84-9 NADwith ready stock and best price
$3E+1/UNIT FOB
2026-10-21
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
From Coffee Waste to Superfood Additive: EU Declares Pectin-Rich Arabica Extract Safe for Food Use
-
Australia Approves Lab-Grown “Milk Sugar” for Babies—A Breakthrough in Infant Nutrition
-
U.S. 10% Temporary Tariff Expires, New Section 301 Tariffs Not Yet Implemented
-
Profits Are Rising, but So Are the Risks—China’s Coatings Industry Is Living Through Its Most Awkward Year
-
Crude Tanker Freight From the Americas to Asia Tops $80 Million per Voyage Amid Global Shipping Crunch
-
“Clearing the Floor”: DKSH’s Privatization of Its Malaysian Subsidiary Signals a Silent Power Shift in Asia’s Supply Chain
-
Canada Scraps PV Module Tariffs! Market Reopens, Demand for Supporting Chinese Chemical New Materials Set to Take Off
-
When SWIFT Goes On-Chain: A New 24/7 Order for Cross-Border Payments
-
MDI Price Surge Hits EMEAI: Is This a Market Correction or the Beginning of a Supply Crisis?
-
“Deregulation” or “Concession”? The Hidden Crisis Behind India’s Repeal of QCOs on Seven Key Petrochemicals
Recommend Reading
-
![US Tariff Refunds Could Reshape Seafood Trade]()
US Tariff Refunds Could Reshape Seafood Trade
-
![Hormuz Closure Raises Cold-Chain Risk]()
Hormuz Closure Raises Cold-Chain Risk
-
![Egypt’s Chemical Surge: $9.4 Billion Export Boom Signals Industrial Powerhouse Rise]()
Egypt’s Chemical Surge: $9.4 Billion Export Boom Signals Industrial Powerhouse Rise
-
![Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28]()
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
![“Milk Sugar 2.0” Cleared for Takeoff: EU Greenlights Next-Gen Human-Identical Oligosaccharide for Infant Nutrition]()
“Milk Sugar 2.0” Cleared for Takeoff: EU Greenlights Next-Gen Human-Identical Oligosaccharide for Infant Nutrition
-
![EU Set to Seek Import Quotas on PET, Epoxy Resins and Fibreglass as Trade Curbs Reach Chemicals]()
EU Set to Seek Import Quotas on PET, Epoxy Resins and Fibreglass as Trade Curbs Reach Chemicals
-
![Acrylic Prices Soar by Over 1 Year—Short-Term at High Levels, Medium-Term Under Pressure]()
Acrylic Prices Soar by Over 1 Year—Short-Term at High Levels, Medium-Term Under Pressure
-
![Both Supply and Demand Surge, Formic Acid Prices Gradually Rise]()
Both Supply and Demand Surge, Formic Acid Prices Gradually Rise
-
![March China Titanium Dioxide Market Prices Rise]()
March China Titanium Dioxide Market Prices Rise
-
![Both Supply and Demand Tightening Drives Butadiene Prices Up Sharply in March]()
Both Supply and Demand Tightening Drives Butadiene Prices Up Sharply in March
